LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept As the prevalence of obesity rises, there is a requirement for new treatments to improve the management of body weight and metabolic health
5EG), and the expression of CBS (Fig
Contact your GP within 2448 hours for: Persistent pale or grey stools without jaundice Unexplained changes in stool colour lasting more than a few days Greasy, foul-smelling stools that float (steatorrhoea) suggesting fat malabsorption Stool changes accompanied by unexplained weight loss, fever, or night sweats Severe or persistent diarrhoea (more than seven days) or constipation unresponsive to usual measures It is particularly important to report stool changes if you have a history of gallbladder disease, pancreatitis, or inflammatory bowel conditions
Subtle metabolic changes : You may notice reduced cravings for certain foods, particularly high-sugar or high-fat options